N. Yasuda

Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study

Y. Kumagai, I. Ieiri, T. Imai, 2019, Journal of clinical pharmacology.

Comparison of medically versus surgically treated acute type a aortic dissection in patients <80 years old versus patients ≥80 years old.

Toshihisa Hirai, Toshikazu Tanaka, T. Yuasa, 2011, The American journal of cardiology.

Clinical outcomes and prognostic factor for acute heart failure in nonagenarians: impact of hypoalbuminemia on mortality.

Toshihisa Hirai, Toshikazu Tanaka, Satoshi Yanagisawa, 2010, International journal of cardiology.

Role of Anti‐Fractalkine Antibody in Suppression of Joint Destruction by Inhibiting Migration of Osteoclast Precursors to the Synovium in Experimental Arthritis

F. Sugiyama, T. Imai, N. Ishii, 2019, Arthritis & rheumatology.

Blockade of the fractalkine-CX3CR1 axis ameliorates experimental colitis by dislodging venous crawling monocytes.

H. Onodera, T. Imai, T. Nakatani, 2019, International immunology.

Long-term Safety and Efficacy of E6011, an Anti-fractalkine Monoclonal Antibody, in Patients with Rheumatoid Arthritis Inadequately Responding to Methotrexate.

H. Yamanaka, T. Takeuchi, T. Imai, 2023, Modern rheumatology.

Long-term Evaluation of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients with Rheumatoid Arthritis Inadequately Responding to Biological Disease-modifying Antirheumatic Drugs.

H. Yamanaka, T. Takeuchi, T. Imai, 2023, Modern rheumatology.

Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases

Yoshiya Tanaka, T. Imai, Y. Kuboi, 2020, ImmunoTargets and therapy.

The Fractalkine‐CX3CR1 Axis Regulates Non‐inflammatory Osteoclastogenesis by Enhancing Precursor Cell Survival

K. Matsuo, Y. Kuroda, T. Imai, 2022, JBMR plus.

The prognostic value of treadmill exercise testing in very elderly patients: heart rate recovery as a predictor of mortality in octogenarians.

Toshihisa Hirai, Toshikazu Tanaka, Satoshi Yanagisawa, 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs

H. Yamanaka, Yoshiya Tanaka, T. Takeuchi, 2021, Modern Rheumatology.

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study

H. Yamanaka, Yoshiya Tanaka, T. Takeuchi, 2020, Arthritis & rheumatology.

Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis

Yoshiya Tanaka, T. Takeuchi, T. Imai, 2018, Modern rheumatology.

Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway

T. Imai, N. Yasuda, 2016, Inflammation and regeneration.

Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway

T. Imai, N. Yasuda, 2016, Inflammation and regeneration.

Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction?

Toshihisa Hirai, A. Tanaka, Toshikazu Tanaka, 2011, Internal medicine.